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ABSTRACT 
The metabolism of cholesterol and bile acids is tightly controlled but only partially 
characterized. The liver is responsible for most of the clearance and catabolism of plasma 
cholesterol, and the hepatocyte expression of LDL receptors is central in this process. The 
major pathways for net excretion of cholesterol from the body are through biliary excretion as 
free cholesterol or after conversion to bile acids. Through activation of the nuclear receptor 
FXR and the G protein-coupled receptor TGR5, bile acids regulate not only their own 
homeostasis but also lipid, glucose and energy metabolism. The overall aim of this thesis was 
to further characterize the regulation of cholesterol and bile acid metabolism in relation to 
plasma lipoproteins.  
Bile acid synthesis is regulated by negative feedback mechanisms. Bile acids mediate 
inhibition of the rate limiting enzyme in bile acid synthesis, CYP7A1, through activation of 
FXR in the liver and in the intestine via the FXR-SHP pathway and the FXR-FGF19-FGFR 
pathway, respectively. In paper I, we demonstrate that circulating FGF19 is markedly 
influenced by transintestinal flux of bile acids whereas its proposed role in the suppression of 
bile acid synthesis and triglyceride levels may not always apply. 
PCSK9 regulates the number of LDL receptors by targeting the LDL receptors for 
degradation. In paper II, we show that circulating PCSK9 has a diurnal rhythm synchronous 
with cholesterol synthesis. We also describe how fasting strongly reduces circulating PCSK9 
and reduces cholesterol synthesis, whereas plasma LDL-cholesterol is unchanged in healthy 
subjects. Furthermore we show that a ketogenic diet induces cholesterol synthesis and 
increase plasma cholesterol whereas circulating PCSK9 is unaltered. 
Diet composition and eating patterns influence cholesterol metabolism. Knowledge of 
underlying mechanisms provides the ability to modulate regulation and homeostasis in a 
desired direction. In paper III, we show that a vegan diet reduces serum total cholesterol and 
LDL-cholesterol. In paper IV, we further explore possible mechanism(s) implicated in this 
dietary effect, but cannot find evidence for any involvement of PCSK9 or altered bile acid or 
cholesterol synthesis. In summary, the work presented in this thesis contributes to the 
understanding of lipid metabolism, and may in a longer term assist in the development of 
better treatment for lipid disorders.  
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1 INTRODUCTION 
Cholesterol is an essential structural component in cell membranes where it helps to generate 
semipermeable barriers between cellular compartments and to regulate membrane fluidity 
influencing several transmembrane signaling processes. It is also a precursor of steroid 
hormones and bile acids. Plasma cholesterol is of major importance in the pathogenesis of 
atherosclerosis, and understanding of cholesterol metabolism has enabled the development of 
drugs and dietary treatments to reduce risk for cardiovascular events. The most important 
pathways for net excretion of cholesterol from the body are in the bile as free cholesterol or 
after conversion to bile acids. Through activation of the nuclear receptor farnesoid X receptor 
(FXR) and the G protein-coupled bile acid receptor 1 (TGR5) [1, 2] bile acids regulate lipid, 
glucose and energy metabolism. Animal studies provide valuable information; however, there 
are species differences. This thesis is based on human studies. 
1.1 LIPID AND LIPOPROTEIN METABOLISM 
In plasma, triglycerides and cholesterol are transported in lipoproteins. Cholesterol is present 
either as free cholesterol or combined with a long-chain fatty acid as cholesteryl esters, the 
storage form. Lipoprotein particles are generally spherical with a surface monolayer of 
phospholipids and unesterified cholesterol which surrounds a neutral lipid core consisting of 
triglycerides and cholesteryl esters. Lipoproteins also contain one or more apolipoproteins 
(apos) that provide structural stability and act as ligands for specific cell surface receptors or 
as activators of enzymatic reactions. Apos define the function and metabolic fate of 
lipoproteins. Circulating lipoproteins exchange their lipid and protein components between 
each other and as a result change in size, shape and density. According to their density, 
lipoproteins are categorized into five main groups: chylomicrons, very low density 
lipoproteins (VLDL), intermediate density lipoproteins (IDL), low density lipoproteins 
(LDL), and high density lipoproteins (HDL) (Table 1).  
Lipoprotein metabolism consists of (i) the exogenous pathway, i.e. postprandial absorption of 
dietary lipids in the intestine and transport to peripheral tissue and the liver, (ii) the 
endogenous pathway, which is the transport of endogenously synthesized triglycerides and 
cholesterol from the liver to peripheral tissues via the VLDL-IDL-LDL pathway, and (iii) 
reverse cholesterol transport in which cholesterol is transported from peripheral tissues back 
to the liver. 
1.1.1 Exogenous pathway 
After a meal dietary lipids (triglycerides, phospholipids and cholesteryl esters) are 
emulsified with bile acids, hydrolyzed by different pancreatic lipases and inserted into mixed 
bile acid micelles [3-5]. Cholesterol is transported across the brush border membrane by 
cholesterol transporters, and free fatty acids (FFAs) are transported across the brush border 
membrane by passive diffusion and by fatty acid transporters. Within the enterocyte FFAs are 
transferred to the endoplamatic reticulum (ER) and re-esterified into triglycerides.  
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The cellular mechanisms by which apoB containing lipoproteins, chylomicrons and VLDLs, 
are assembled are similar. However, intestinal apoB is made as a truncated form, apoB48, 
which is 48% of the full-length protein expressed in the liver referred to as apoB100. ApoB48 
cannot bind to the LDL receptor (LDLR). The assembly of apoB containing lipoproteins is 
not fully defined, but three components are recognized as necessary; apoB, microsomal 
transfer protein (MTP), and lipids that form the neutral lipid core and membrane. The main 
site of regulation of assembly is believed to be degradation of the nascent apoB polypeptide 
[3, 6, 7]. It has been suggested that enterocytes and hepatocytes may have different methods 
of apoB stabilization. As the apoB protein is translated by ribosomes it crosses into the ER, 
and triglycerides are added co-translationally to the elongating apoB protein (ie apoB is 
lipidated). To further promote lipoprotein formation MTP also shuttles cholesteryl esters and 
phospholipids [3]. Mature chylomicrons are released into the lymph, from where they will 
reach the systemic blood. Each chylomicron and VLDL particle contains one single molecule 
of apoB. ApoB is a non-exchangeable apoprotein and remains with the lipoprotein particle 
until the particle is removed from the circulation through cellular uptake. The primary 
function of apoB containing lipoproteins is to deliver fatty acids in the form of triglycerides 
to muscle for ATP biogenesis and to adipose tissue for long term storage. 
 
Table 1. Characteristics of the major lipoprotein classes. 
Lipoprotein Density 
(g/mL) 
Diameter 
(nm) 
TG % Chol % PL % Protein % 
Chylomicron 0.93 75-1200 80-95 2-5 3-8 1-2 
VLDL 0.930-1.006 30-80 50 22 19 8 
IDL 1.006-1.019 25-35 20 38 23 19 
LDL 1.019-1.063 18-25 11 47 22 21 
HDL 1.063-1.21 5-12 6 15-22 23-30 55 
Percent composition by weight 
 
Within the circulation, lipoprotein lipase (LPL) mediates hydrolysis of triglyceride rich 
lipoproteins (figure 1). LPL is primarily expressed attached to the capillary endothelium in 
tissues that oxidize or store fatty acids in large quantities, such as skeletal muscle, heart, and 
white and brown adipose tissue [8, 9]. ApoCII acts as a cofactor and apoCIII as an inhibitor 
of LPL. Changes in LPL expression occur through the action of hormones such as insulin, 
glucocorticoids and adrenaline [10] . Epidemiological studies reveal that mutations in apoCIII 
are linked to decreased risk for cardiovascular disease (CVD) and coronary heart disease risk 
in humans [11, 12]. 
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Figure 1. Simplified schematic representation of the exogenous pathway. Absorption of 
dietary lipids in the intestine and transport to the peripheral tissue and the liver. TG, 
triglyceride; C, cholesterol; PL, phospholipids; A, apoA; B-48, apoB-48; C, apoC; E, apoE. 
 
As LPL continuously hydrolyzes triglycerides from chylomicrons and VLDL particles the 
particles gradually become depleted of triglycerides, relative enriched in cholesterol, less 
negatively charged and small enough to enter the space of Disse. The particles lose affinity 
for LPL and dissociate (figure 1). The exchangeable apos CI, CII, CIII are transferred back to 
HDL in exchange for apoE which serves as a ligand for receptor mediated clearance by the 
liver (among other functions HDL particles serves as a reservoir for exchangeable 
apoproteins). Uptake of chylomicrons and VLDL remnants into hepatocytes are mediated by 
the LDL receptor (LDLR), the LDL-receptor related protein (LRP), a complex formed 
between LRP and heparan sulphate proteoglycan (HSPG) or HSPG alone [13]. In normal 
individuals, the intravascular metabolism of chylomicrons and chylomicron remnants is 
estimated to 10-15 and 30 minutes, respectively. 
1.1.2 The endogenous pathway 
To secrete triglycerides and cholesterol, hepatocytes assemble VLDL particles. In 
hepatocytes lipidation of apoB100 by the action of MTP gives rise to pre VLDLs which are 
further processed to become triglyceride-poor VLDL2 particles. These are either transferred 
through the secretory pathway to be secreted from the cell, or acquire more lipids in the Golgi 
apparatus to become triglyceride rich VLDL1 particles [6, 14, 15] (figure 2). Similar to 
chylomicron formation, the assembly of VLDL is dependent on availability of lipids. Fatty 
acid (FA) sources for VLDL-triglyceride include  (i) dietary FAs that have reached the liver 
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via chylomicron uptake  (ii) FAs synthesized de novo in the liver from carbohydrates, acetyl 
CoA and malonyl CoA [16]  (iii) Non esterified FAs  (NEFA) derived from adipose tissue,  
(iv) NEFA derived from the spillover of chylomicron triglycerides and  (v) FAs stored in 
liver lipid droplets [15, 17]. 
 
 
 
Figure 2. Simplified schematic representation of the endogenous pathway. The endogenous 
pathway transport triglycerides and cholesterol from the liver to the peripheral tissues via the 
VLDL-IDL-LDL pathway. TG, triglyceride; C, cholesterol; VLDL, very low density 
lipoprotein, IDL, intermediate density lipoprotein; LDL, low density lipoprotein; LDLR, LDL 
receptor; A, apoA; B-100, apoB-100; C, apoC; E, apoE; 
 
As triglycerides are removed by the action of LPL the density increases, large triglyceride 
rich VLDL1 particles become smaller VLDL2 and subsequently IDL (VLDL remnants). 
After exchange of apos with HDL, IDL can be further hydrolyzed by hepatic lipase to LDL. 
LDL particles are cholesteryl ester enriched lipoproteins with apoB as their only apoprotein, 
and are catabolized mainly by hepatic uptake through LDL receptors [15]. The LDL receptor 
is a cell surface receptor capable to bind and internalize lipoproteins containing apoB100 and 
apoE. In normal humans, the half-life of VLDL particles is 1-2 hours, and that of LDL 
particles 2-3 days. Accordingly, in the fasting state LDL cholesterol accounts for 
approximately 65-75% of total plasma cholesterol. 
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1.1.3 Reverse cholesterol transport and HDL metabolism  
Most cells in the body are capable of synthesize all of the cholesterol they require but not to 
catabolize cholesterol. The reverse cholesterol transport pathway removes cholesterol from 
peripheral tissue –including lipid laden macrophages in the artery wall– to the liver for 
excretion into bile as unesterifed cholesterol or after conversion to bile acids [18-20]. HDL 
has a key role in cholesterol efflux from cells, and as a transporter of cholesterol thorough 
plasma to the liver. 
HDL formation begins when lipid poor apoAI is secreted by the liver or intestine though 
interaction with the transporter ABCA1 in the hepatocyte or enterocyte. Lipid-free/lipid poor 
apoAI is also continuously being generated during the remodeling of mature HDLs [18, 21]. 
ApoAI is the main apoprotein in HDL and participates in the formation of HDL as well as 
interaction with scavenger receptor B-1 (SR-B1), the principal HDL receptor. SR-B1 is an 
integral membrane protein primarily expressed in the liver, steroidogenic tissues, and 
endothelial cells. HDL heterogeneity is a consequence of constant remodeling by various 
factors. Two circulating proteins responsible for intravascular maturation of HDL are lecithin 
cholesterol acyl transferase (LCAT) and phospholipid transfer protein (PLTP). Further, 
hepatic lipase and endothelial lipase are important for HDL remodeling [18, 21, 22]. HDL-
cholesteryl esters can be transferred by  the enzyme cholesteryl ester transferase (CETP) to 
VLDL/IDL/LDL in exchange for triglycerides [22]. The actions of CETP result in decreased 
HDL-cholesterol concentrations and cholesterol enriched LDL-cholesterol. SR-B1 mediates 
selective removal of cholesteryl esters, TGs, phospholipids and vitamin E from the HDL core 
into the cell  without endocytotic uptake and degradation of the whole HDL particle [23]. As 
mentioned above, ABCA1 mediates lipid efflux to lipid poor apoA1. A second transporter, 
ABCG1, mediates further cholesterol efflux to lipidated HDL.  
Epidemiological studies have shown that plasma HDL levels inversely correlate with 
atherosclerotic cardiovascular disease [24]. However, the failure of several clinical trials with 
drugs that rise HDL levels (niacin [25, 26] and CETP inhibitors [27, 28]), and studies of 
human genetic variants associated with HDL-cholesterol levels [29, 30] have brought the 
“HDL-hypothesis” [24, 31] –which posits that intervention that increase HDL-cholesterol 
will prevent occurrence of CHD– into question.  
1.2 CHOLESTEROL METABOLISM 
Cholesterol is exchanged within and between organelle membranes, and between tissues at 
the whole body level. Cholesterol homeostasis is under tight regulation, and cholesterol levels 
reflect the net effect of de novo synthesis, intestinal absorption of dietary and biliary 
cholesterol, circulatory clearance and excretion. 
1.2.1 Regulation of synthesis 
In humans, cholesterol is derived from two sources – diet and de novo synthesis. All 
nucleated cells can synthesize cholesterol de novo from acetyl CoA through the mevalonate 
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pathway, which occurs in the ER. The rate limiting step in the mevalonate pathway is the 
conversion of HMG-CoA to mevalonate by HMG-CoA reductase. HMG-CoA reductase is an 
integral membrane protein which is under regulation via a negative feedback system 
modulated by the SREBP pathway [32]. In mammalians there are two SREBP genes, 
SREBP1 and SREBP2, that express three major SREBP proteins. SREBP1a and SREBP1c 
are produced from the same gene by use of different promoters and alternative splicing. The 
isoforms SREBP1a and SREBP1c are more active in transcription of genes involved in fatty 
acid synthesis, whereas SREBP2 is the main regulator of cholesterol metabolism (e.g. 
HMGCoA reductase, LDLR and PCSK9) [33-36]. SREBP resides in the ER and is activated 
in sterol poor conditions. Simply, SREBP2 activation increases the transcription of gene 
products that function to increase cellular cholesterol levels, such as HMGCoA reductase and 
the LDLR. When sterol levels are restored, cholesterol synthesis and uptake are coordinately 
suppressed. Cholesterol synthesis has a diurnal rhythm with a nadir during the day and peak 
levels during the night from midnight to 4:00, both in humans and rats [37-39]. Insulin and 
thyroid hormone increase HMG-CoA reductase activity whereas glucagon and 
glucocorticoids decrease it. HMG CoA reductase inhibitors, statins, competitively inhibit the 
enzymatic activity of HMG CoA reductase. The total cholesterol content of a human body 
(70 kg) is about 140 g of which slightly less than 1% (~1200 mg) turns over daily [40].  
1.2.2 Cholesterol absorption 
Whereas dietary triglycerides are almost completely absorbed, only 30-50% of the cholesterol 
present in the intestinal lumen (dietary 300-500mg/day and biliary 600-1000 mg/day) is 
absorbed. Dietary and biliary cholesterol is transported across the brush border in the 
proximal jejunum principally via Niemann-Pick C1 Like 1 (NPC1L1) [41] and further 
transported to ER for esterification by the action of acyl coenzyme A:cholesterol 
acyltransferase 2 (ACAT2). Sitosterol and other non-cholesterol sterols are less effective 
substrates for ACAT2 and are preferentially secreted back into the intestinal lumen through 
the paired half-transporters  ATP-binding cassette subfamily G member 5 and ATP-binding 
cassette subfamily G member 8 (ABCG5/G8). In the liver, hepatic ABCG5/G8 facilitates 
biliary secretion of cholesterol and plant sterols [42]. 
In addition to chylomicron assembly, some studies also suggest that HDL assembly and 
secretion by the intestine may play a role in absorption of cholesterol and phospholipids [5]. 
Cholesterol absorption is inhibited by drugs such as ezetimibe [43], which inhibits the 
activity of NPC1L1. 
1.2.3 Cholesterol excretion 
Most cells in the body cannot catabolize cholesterol. Small amounts of cholesterol are lost 
from the body through the excretion of steroid hormones in the urine, and through the 
sequestration of dead cells from the skin. The role of cholesterol elimination through the 
excretion of dead intestinal cells is less clear, as is the possible potential of active secretion of 
plasma lipoprotein-derived cholesterol by enterocytes, a process referred to as transintestinal 
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cholesterol excretion (TICE) [44, 45]. The most important pathways for net excretion from 
the body are through hepatic elimination, which can also be actively regulated by dietary and 
pharmacological treatments. This occurs either through direct secretion of free cholesterol 
into the bile, or after conversion of cholesterol to bile acids (figure 3 and 6).  
 
 
 
 
 
1.2.4 The LDL receptor and PCSK9 
The liver is responsible for the clearance and catabolism of plasma LDL and hepatocyte 
expression of LDLR is central to this process [46]. Upon LDL binding to the LDLR, the 
receptor-ligand complex is internalized into the hepatocyte via clathrin-coated pits. The 
vesicles containing the internalized LDL-LDLR complex fuse with endosomes resulting in 
dissociation of the LDL particles from the LDLR due to the acidic environment. Cholesterol 
is recovered and distributed in the cell. The LDLRs are then transported to the surface of the 
hepatocyte to bind and clear additional LDL [46].  
PCSK9, a serine protease, enhances the post translational degradation of the LDLR. 
Circulating PCSK9 binds to the LDLR on the surface of the hepatocyte and the complex is 
internalized within the endosome. The LDL-PCSK9 complex is then routed to the lysosome 
for degradation, thereby preventing recycling of LDLR (figure 4). The expression of both 
LDLRs and PCSK9 is regulated by SREBP2 and upregulated when intracellular cholesterol 
levels are low. While SREBPs increase the number of LDLRs, they also increase PCSK9 
expression, resulting in an increased degradation of LDLRs and reduced clearance of LDL 
particles [47]. 
Figure 3. Simplified overview 
of cholesterol metabolism and 
enterohepatic circulation 
of bile acids.   
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Figure 4. Simplified schematic representation of the role of PCSK9 in the regulation of 
LDL cholesterol. Recycling of LDLRs enables efficient clearance of LDL particles. 
Circulating PCSK9 regulates the recycling of LDLRs by targeting the LDLR for degradation. 
By preventing LDLR from recycling back to the surface, PCSK9 reduces the number of 
LDLRs on hepatocytes, resulting in reduced LDL clearance rates and elevated levels of 
plasma. PCSK9 also appears to enhance degradation of the LDLR via an intracellular 
pathway. 
 
PCSK9 was first connected to cholesterol metabolism when gain-of-function mutations were 
identified in two French families with familial hypercholesterolemia (FH) who did not have 
mutations in the LDLR or APOB genes [48]. Loss-of-function mutations are instead 
associated with low LDL-C and low lifetime risk of cardiovascular disease [49, 50]. PCSK9 
is expressed predominantly in the liver, intestine, kidney and nervous system [51]. PCSK9 
can promote the degradation of other cell surface receptors including structural homologs of 
the LDLR (VLDL receptor and apoE receptor) [52] and CD36 [53]. CD36 functions as a 
scavenger receptor that among other things binds oxidatively modified LDL particles, 
apoptotic cells and facilitates transport of  long chain fatty acids into cells[54]. CD36 
participates in muscle lipid utilization, gut fat absorption and triglyceride storage [53, 54]. 
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Moreover, PCSK9 also appears to enhance the degradation of LDLRs by a yet incompletely 
defined intracellular pathway, which does not require PCSK9 to be secreted [55]. Levels of 
circulating PCSK9 are higher in women than in men, and in postmenopausal compared to 
premenopausal females [56, 57]. Inhibiting PCSK9 production with small interfering RNA 
[58] or using monoclonal antibodies [59] lowers LDL-C levels, and is currently a very active 
area of therapeutic development. 
1.3 BILE ACID METABOLISM 
1.3.1 Bile acid synthesis 
The liver is crucial for metabolic homeostasis, and in the liver hepatocytes are the cells 
responsible for most of the synthetic and metabolic functions. Hepatocytes are polar cells 
with a canalicular and a sinousidal surface [60]. Unlike capillaries elsewhere, the liver 
sinusoidal endothelial cells lack basal membrane and are perforated with pores (fenestrae) 
[61-63], that allow free egress of solutes from the sinusoidal blood to the space of Disse.  
In the adult human liver approximately 500 mg cholesterol is converted into bile acids each 
day. Both the steroid nucleus and the side chain of cholesterol are modified during bile acid 
synthesis, and the result is a marked change in the physicochemical properties. The 
amphipathic property enables bile acids to emulsify lipids and enhance the absorption of 
lipids and fat soluble vitamins in the intestine. The detergent properties of bile acids are 
determined by the number and orientation of the hydroxyl groups and by the presence or 
absence of an amino acid moiety. The hydrophobicity increases as follows  ursodeoxycholic 
acid (UDCA), cholic acid (CA), chenodeoxycholic acid (CDCA), deoxycholic acid (DCA), 
and lithocholic aicd (LCA) [64]. Bile acid synthesis occurs in pericentral hepatocytes and 
involves enzymes located in the ER, mitocondria, cytosol and peroxisomes [65, 66]. Bile 
acids are synthesized via two pathways, the classical or neutral, and the alternative or acidic 
pathway (figure 5). The classical pathway is the major pathway of synthesis and accounts for 
more than 90% of the total bile acid synthesis in humans. In man, two bile acids are 
synthesized from cholesterol in the liver: CDCA (3α, 7α-dihydroxy) and CA (3α, 7α, 12α-
trihydroxy). 
In the classical pathway the first and rate limiting step is the hydroxylation at the carbon C-7 
mediated by cholesterol 7α-hydroxylase (CYP7A1) located in the ER. Then 3β-
hydroxysteroid hydrogenase (HSD3B7) converts 7α-hydroxycholesterol to 7α-hydroxy-4-
cholesten-3-one (C4). C4 is a precursor for CA and CDCA and can be used as a serum 
marker for bile acid synthesis [67, 68]. C4 is converted to 7α, 12α-dihydroxy-4-cholesten-3-
one by a sterol 12α-hydroxylase (CYP8B1) leading to synthesis of CA. Without 12α-
hydroxylation by CYP8B1, C4 is eventually converted to CDCA. The mitochondrial sterol 
27-hydroxylase (CYP27A1) catalyzes the steroid chain oxidation in both CA and CDCA 
synthesis. The enzyme CYP7A1 is largely determining the bile acid pool size whereas 
CYP8B1 is considered important for the CA/CDCA ratio in the bile acid pool [69]. 
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In the alternative pathway cholesterol is first converted to 27-hydroxycholesterol by 
CYP27A1. Oxysterol 7α-hydroxylase (CYP7B1) catalyzes hydroxylation of 27-
hydroxcholesterol to 3β,7α-dihydroxy-5-cholestenoic acid, which  eventually is converted to 
CDCA. Primary bile acids synthesized from cholesterol in the liver are further metabolized 
into secondary and tertiary bile acids by the gut microbiota. 
In the hepatocyte bile acids are conjugated to glycine or taurine preceding secretion into the 
bile canicula [70]. In addition to amidation, bile acids may undergo sulphation, 
glucuronidation, and N-acetylaminoglucosidation. Conjugation increases the amphipathicity 
and enhances the solubility of the molecules, which makes them impermeable to cell 
membranes. Several bile acid transporter proteins ensure proper excretion and uptake. Bile 
acid transporters have different transport affinities for various bile acids species, but also for 
other endogenous and exogenous compounds such as toxins and drugs [71]. Efficient hepatic 
excretion, intestinal reabsorption, and hepatic uptake of bile acids restrict bile acids to 
hepatobiliary and intestinal compartments. Bile acid transporters and bile acid synthesis is 
under strict and coordinated regulation via nuclear receptors. 
 
 
 
Figure 5. Bile acid synthesis  
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1.3.2 The enterohepatic circulation of bile acids 
In the enterohepatic circulation, bile acids circulate between the liver and the intestine. A bile 
acid pool of about 2-3g circulate between 4-8 times per day dependent on dietary regimen in 
humans. Bile acids lost in feces (0.5-0.8g/day) are replaced by de novo synthesis from 
cholesterol in the liver to maintain a constant bile acid pool size. 
Bile acids are actively transported into bile caniliculi by the bile salt export pump (BSEP; 
encoded by the ABCB11 gene). In the alkaline bile (pH7.6-8.4) conjugated bile acids are 
present as ionic salts, and therefore often referred to as bile salts. Bile formation is an osmotic 
process and the most important solutes driving bile formation are bile salts. To protect the 
canalicular membrane from bile acid mediated solubilization, phospholipids are excreted into 
bile to form mixed micelles with bile acids [72]. Cholesterol excretion into bile is mediated 
by the ABCG5/ABCG8 heterodimer. Bile flows in bile canaliculi which drain into bile ducts. 
The ducts join to form larger and larger channels, the so called biliary tree. A fraction of the 
bile acids are absorbed by cholangiocytes (the epithelial cells lining the biliary tract) and 
recycled back to hepatocytes, the cholangiohepatic shunt [73, 74]. The physiological 
relevance of this mechanism is unclear.  
Upon delivery of chyme from the stomach into the duodenum cholecystokinin (CCK) will be 
released from the intestinal mucosa into plasma. CCK stimulates relaxation of the sphincter 
of Oddi, contraction of the gallbladder and the common bile duct to release bile acids into the 
intestine. In the ileum bile acids are efficiently reabsorbed (>95%), mainly by active 
transport. conjugated bile acids are transported across the apical brush border membrane by 
the apical sodium-dependent bile acid transporter (ASBT,  SLC10A2). The bile acids are 
translocated to the basolateral membrane of the enterocyte by the cytosolic intestinal bile acid 
binding protein (IBABP) and subsequently transported across the basolateral membrane into 
portal blood by the heteromeric organic solute transporter (OST) OSTα-OSTβ [75, 76]. The 
fraction of bile acids not reabsorbed by active transport nor passive diffusion continues 
through the lumen and becomes subjected to bacterial modification. The major bile salt 
modifications by gut microbiota in the human large intestine include deconjugation, oxidation 
of hydroxy groups, and 7α/β-dehydroxylation [77]. In humans, when CDCA undergoes 7-
dehydoxylation, LCA (3α-hydroxy) is formed. When cholic acid undergoes 7-
dehydroxylation, DCA (3α, 12α-dihydroxy) is formed. Deconjugation and 7α/β-
dehydroxylation of bile salts increases their hydrophobicity, thereby permitting passive 
absorption. Reclaimed secondary bile acids join the primary bile acids in portal blood.  
The sodium-taurocholate cotransporting polypeptide (NTCP, encoded by SLC10A1) is the 
primary mechanism for hepatic uptake of bile acids from portal blood, which complete the 
enterohepatic cycle of bile acids. Preceding transport across the canalicular membrane by 
BSEP, both recovered and de novo synthesized bile acids are conjugated. NTPC’s major 
physiological substrates include all the major glycine and taurine conjugated bile acids. 
Unconjugated bile acid are moderate or weak substrates [78]. Organic anion transporting 
polypeptides (OATPs) show substrate specificity for unconjugated bile acids [79]. The uptake 
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of bile acids from portal blood is efficient with a first pass clearance of  ̴ 80% [80] and occurs 
in direct proportion to concentration. The major bile acid transporters that control 
enterohepatic circulation are BSEP, ASBT, OSTα/OSTβ, NTCP and OATP [81] (figure 6). 
1.3.3 Regulation of bile acid synthesis  
Bile acid synthesis is regulated by negative feedback mechanisms. Bile acids mediate 
inhibition of the rate limiting enzyme in bile acid synthesis, CYP7A1, through activation of 
the nuclear receptor FXR in the liver and in the intestine. In the liver FXR induces a 
regulatory cascade involving SHP by which the expression of CYP7A1 is inhibited (figure 6). 
Thus, upon activation FXR transcriptionally induces small heterodimer partner (SHP, 
NR0B2), which acts as a corepressor to inhibit the transcriptional activity of liver related 
homolog-1 (LRH-1) and hepatocyte nuclear factor 4α (HNF4α) that positively regulate the 
expression of CYP7A1 and CYP8B1 [82, 83]. In the intestine; bile acid activated intestinal 
FXR induces FGF15 in mice, which is released into portal blood. In the liver, FGF15 binds to 
the FGFR4/β-klotho complex on the basolateral membrane of the hepatocyte to initiate 
intracellular signaling pathways, such as extracellular signal-regulated kinase (ERK), protein 
kinase C, and c-Jun N-terminal kinase (JNK) that represses Cyp7A1 mRNA [84, 85]. The 
human orthologue of FGF15 is FGF19. 
The postulated role of FGF15/19 as an intestinal factor in the regulation of bile acid synthesis 
is based on several observations. Studies in rats showed that intraduodenal but not 
intravenous infusion of tauro CA repressed CYP7A1 mRNA expression. In mice suppression 
of Cyp7a1 by bile acids and an FXR agonist was still observed in shp-/- mice, indicating that 
the FXR/SHP/LRH1 cascade was not the only pathway mediating bile acid feedback 
inhibition [86, 87]. Treatment of primary human hepatocytes with FGF19 resulted in 
repression of CYP7A1 [88, 89]. Later it was demonstrated that FGF15 likely was this 
putative intestinal factor [90]. Expressed and induced by FXR in the intestine, but not in liver, 
FGF15 was shown to repress bile acid synthesis through a mechanism that involves FGFR4 
and SHP. In humans, circulating levels of FGF19 were reduced following treatment with the 
bile acid sequestrant cholestyramine, and increased upon feeding CDCA [91]. Circulating 
levels of FGF19 exhibit peaks 90-120 min after the postprandial rise in serum bile acids, 
preceding the decline of bile acid synthesis. The meal-elicited FGF19 increase was abolished 
upon prolonged fasting [91]. In addition to repress bile acid synthesis [90], FGF15/19 is 
believed to regulate postprandial responses such as to repress gluconeogenesis [92, 93], and 
to stimulate glycogen and protein synthesis [94]. Moreover, FGF15/19 is believed to 
stimulate gallbladder filling [95], an effect in part mediated by relaxation of the gallbladder 
smooth muscle [95]. 
FXR is highly expressed in tissues that are exposed to bile acids, including the liver and 
intestine [96, 97]. FXR can be activated by both free an conjugated bile acids; the 
hydrophobic bile acid CDCA is the most potent ligand of FXR, followed by LCA, DCA and 
CA. Bile acids are also ligands for TGR5. Both FXR and TGR5 regulate various elements of 
glucose, lipid and energy metabolism. Both conjugated and free bile acids are known to 
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stimulate TGR5. Among all bile acids TLCA is the most potent TGR5 agonist, followed by 
TDCA, TCDCA and TCA. TGR5 is highly expressed along the intestinal tract, with the 
highest expression found in the ileum and colon [2]. Despite that liver being a major bile acid 
target organ, TGR5 expression in the liver is low [98, 99]. Bile acid composition in mice and 
humans are very different [100]. In man the hydrophobic bile acid pool consist of 40% each 
of CA and CDCA, and 20% DCA. In mice the bile acid pool consists of about 50% CA and 
50% MCA [69] [101].  
 
 
 
Figure 6. Simplified overview of the regulation of bile acid synthesis, and membrane 
transporters in the enterohepatic circulation.   
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2 AIMS 
The specific aims of the present thesis were:  
I. To assess the importance of circulating FGF19 as a regulator of bile acid 
 synthesis in humans and as a possible regulator of serum triglyceride levels 
II. To gain insight into the function of PCSK9 in humans by establishing whether 
 circulating levels are influenced by diurnal, dietary, and hormonal changes 
III. To study the effect of a vegan diet on serum levels of oxidized LDL and 
 atheroprotective antibodies in patients with rheumatoid arthritis 
IV. To assess if changes in circulating PCSK9 or bile acid synthesis may contribute 
 to the effects of a vegan diet 
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3 MATERIAL AND METHODS 
3.1 SUBJECTS AND STUDY DESIGN 
The studies were approved by the regional ethics committee at the Karolinska institutet, 
Stockholm, Sweden. Informed consent was obtained from all participants. 
3.1.1 Paper I 
Ten healthy volunteers (age 30±3, BMI 23±3.3) participated in the study. There were no 
clinical or laboratory signs of endocrine or gastrointestinal disorder, liver disease or diabetes. 
Nine subjects (4 men/ 5 women) participated in each experiment. Eight subjects participated 
in both.  
Two experiments with the bile acid binding sequestrant cholestyramine were performed, a 
three week and a single day treatment, respectively. In the long term treatment, a daily dose 
of 4g was administrated together with breakfast the first week (1x4g). The second and third 
week, cholestyramine was taken together with breakfast and dinner (2x4g and 2x8g, 
respectively). The last dose was administrated together with breakfast day 21. Blood was 
collected after overnight fast day 0, 7, 14, 21-24 and 27. Day 0 and days 21-24, samples were 
collected also at 13:00 and 17:30. The one day drug treatment was studied in a 3-day 
experiment. Cholestyramine was taken together with each meal day 0 (4x4g). Blood was 
collected every 90th minutes for 33 hours, and in the morning after overnight fast day 2 and 
3. The subjects were confined to bed between 22:30-7:00 (day0). 
3.1.2 Paper II 
Samples from nine different studies were analyzed. The participants were patients or healthy 
volunteers.  
1) Five healthy subjects sampled every 90 minutes from 9:00 to 10:30 the next day 
[102]. 
2) Five healthy subjects sampled every 60 minutes from 9:00 to 16:00 during a 
prolonged overnight fast [102]. 
3) Five patients with clinically active rheumatoid arthritis (RA) sampled before and 
during 7 days of fasting [103].  
4) Seven healthy subjects who participated in a study were blood was drawn before and 
after 48 hours of fasting [104].  
5) Sewenteen children with pharmacologically refractory epilepsy consuming a 
ketogenic diet, samples were collected before initiation and during 1-16 month 
follow-up [105].  
6) Cholestyramine was administered to 10 healthy volunteers together with standardized 
meals during one day. Samples was drawn every 90th minute during 33 hours and 
after overnight fast day 2 and 3. 
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7) Twelve healthy volunteers followed over 8 days during 66 hours of fasting and 50 
hours of sleep deprivation in a crossover study [106].  
8) Fifteen healthy men received increasing doses of GH up to 0.1 IU/kg body 
weight/day for three weeks, and samples collected the last week  were analyzed [107]  
9) Ninteen subjects before and after 4 weeks of atorvastatin 80 mg/day treatment.  
3.1.3 Papers III and IV 
The patients and study design have been described in detail in [108]. Sixty-six patients with 
RA according to American college of Rheumatology (ACR) [109] criteria were enrolled in 
the study. The patients were eligible for inclusion if they were between 20 and 69 years of 
age, had disease duration between 2 and 10 years, had not tried dietary manipulations before, 
did not have a history of food allergy and had active disease.  
The patients were on stable doses of non-steroidal anti-inflammatory drugs, oral 
glucoocorticosteroids and disease-modifying anti rheumatic drugs (DMARDs).  
None of the patients used statins or biologic medications before or during the study.  
The patients were randomized to a vegan diet free of gluten (n=38) or a non-vegan diet 
(n=28) for 1 year. The vegan diet contained vegetables, root vegetables, nuts, fruits, 
buckwheat, millet, corn, rice and sunflower seeds. 
3.2 SERUM PCSK9 AND FGF19 ASSAY  
Serum PCSK9 levels (papers II and IV) were determined using a PCSK9 dual monoclonal 
antibody sandwich ELISA developed [110] and modified [111] at Lilly Research 
Laboratories, Eli Lilly and Company, Indianapolis, IN, USA. 
Serum FGF19 was analyzed using a commercially available ELISA (FGF19 Quantikine, 
R&D Systems, Minneapolis, MN, USA).  
3.3 SERUM MARKERS OF CHOLESTEROL AND BILE ACID SYNTHESIS 
Unesterified lathosterol, a marker of total body cholesterol synthesis, was determined by gas 
chromatography–mass spectrometry (GC–MS) [112], and corrected to serum total cholesterol 
[113] (Lathosterol/c) because lathosterol is transported by cholesterol rich lipoproteins  
(Papers I, II and IV). 
The marker for bile acid synthesis, 7α-hydroxy-4-cholesten-3-one (C4), was in paper I 
determined by high performance liquid chromatography (HPLC) as described [68], and 
corrected to total cholesterol [102] (C4c). Serum levels of C4 was in paper IV measured by 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) [114], and corrected to total 
cholesterol [102]. 
Serum bile acids were determined using chemical hydrolysis with ether extraction and GC-
MS (Paper I). 
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3.4 SERUM LIPID AND LIPOPROTEIN ANALYSES 
Total cholesterol and TG were determined using colorimetric reagents (Roche/Hitachi, 
Mannheim, Germany). 
Papers I and IV; Concentrations of lipoprotein cholesterol and TGs in serum were measured 
by fast protein lipid chromatography (FPLC). Lipoproteins were separated by size in a 
column. Reagents (cholesterol and TG) were continuously added to the eluate online 
followed by measurements of absorbance. The respective concentration was calculated by the 
area under the curve. The automated system for size-exclusion chromatography (SEC) of 
lipoproteins is described in detail in [115]. 
Paper III; Concentrations of LDL cholesterol were calculated by Friedewald’s formula based 
on P-cholesterol, P-triglycerides and P-HDL cholesterol. 
3.5 GLUCOSE AND INSULIN ASSAYS  
Serum glucose was determined using an enzymatic colorimetric assay with reagents from 
Roche/Hitaachi, Mannheim, Germany. Insulin was determined by a commercially available 
ELISA (Mercodia Insulin ELISA, Mercodia, Uppsala, Sweden).  
3.6 STATISTICS 
Statistical analyses were performed as described in respective papers.  
 
  25 
4 RESULTS 
4.1 PAPER I 
Effects of short and long term treatment with cholestyramine on bile acid, cholesterol and 
lipoprotein metabolism.  
Aim; To assess the importance of circulating FGF19 as a regulator of bile acid (BA) 
synthesis and serum triglycerides (TGs) in humans.  
Background: A non-tumorigenic FGF19 variant given in supraphysiological concentrations 
suppresses BA synthesis in humans. It is unclear to what extent physiological changes in 
circulating FGF19 contribute to the regulation of BA synthesis in man, relative to BA 
mediated effects via hepatic FXR. BA binding sequestrants, such as cholestyramine, reduce 
circulating levels of FGF19. Two experiments with cholestyramine were performed, a three-
week treatment and a single-day treatment. 
Results: To generate a stepwise reduction of circulating FGF19, weekly increasing doses of 
cholestyramine were administered during three weeks to nine healthy volunteers. Samples 
were collected before, during and after cessation of treatment. During the 3 week 
cholestyramine treatment, a dose dependent reduction in circulating FGF19, increased BA 
synthesis (17-fold) and cholesterol synthesis (4.4-fold) was observed. Total cholesterol, 
particularly LDL cholesterol, was reduced. Levels of serum BAs were not altered. 
After cessation of drug treatment, circulating FGF19 gradually increased from suppressed to 
increased compare to basal value.  The strongly induced BA synthesis was gradually reduced 
and returned to normal 6 days post cessation. Cholesterol synthesis was still increased 6 days 
after drug cessation, whereas serum cholesterol was reduced. Serum TG and glucose 
remained unchanged throughout the experiment. Total serum bile acids were not changed at 3 
days after drug cessation compared to baseline, but were elevated 6 days after drug cessation.  
The experimental set-up with one day’s drug treatment and sampling every 90th min for 
33hrs and additional samples drawn after overnight fast day 2 and 3, revealed rapid dynamic 
changes: During the night after a single day of treatment, TG strongly increased, peaked and 
declined to be doubled before breakfast. Further, glucose and insulin transiently increased 
during the night. In the morning after a single day of treatment FGF19 levels was reduced by 
90% compared to baseline, while BA synthesis (reflected by C4c levels) and cholesterol 
synthesis (reflected by lathosterol/c levels) were increased by 4 and 1.6-fold, respectively. 
Levels of serum BAs were unchanged, however, elevated day 2 (after overnight fast). The 
diurnal rhythms of BA and cholesterol synthesis were altered during the treatment and the 
alterations persisted throughout the following day. C4c and lathosterol levels were still 
elevated on days 2 and 3 compared to basal values.  
 
  26 
Conclusion; Serum TG is not influenced by the degree of increase in BA synthesis. It is 
unlikely that circulating FGF19 levels mediate the BA-induced changes in serum TG. 
Circulating levels of FGF19 may not be the primary mediator of suppression of BA synthesis 
in humans. 
4.2 PAPER II 
Circulating PCSK9 has a diurnal rhythm synchronous with cholesterol synthesis and is 
reduced by fasting in humans. 
The aim of the present study was to gain insight into the function of PCSK9 in humans by 
establishing whether circulating levels are influenced by diurnal and dietary changes.  
Results: To answer these questions nine different studies, including 90 subjects, were 
analyzed. We first found that the levels of circulating PCSK9 showed a diurnal rhythm with a 
nadir between 3 pm and 9 pm and with a peak early morning. These distinct diurnal changes 
were similar to those observed for lathosterol, a marker for cholesterol synthesis. Despite 
these pronounced changes in circulating PCSK9 and cholesterol synthesis, serum cholesterol 
levels remained stable. To evaluate if food intake was related to the reduction of PCSK9 seen 
between breakfast and 4pm, samples from a study with prolonged overnight fast were 
analyzed.  Circulating PCSK9 was reduced to similar extent between 9 am and 4 pm as when 
food was ingested.  
Next we evaluated how a rapid and pronounced hepatic demand for cholesterol would 
influence circulating PCSK9. In the experiment analyzed, ten healthy subjects received 
cholestyramine together with standardized meals for one day. The treatment practically 
abolished the diurnal rhythm of PCSK9 and lathosterol the following day.  
To further investigate parallel temporal changes of circulating PCSK9 and cholesterol 
synthesis, samples from a study designed to evaluate survival strategy at authentic outdoor 
conditions were analyzed. Up to 66 hours of fasting was compared with up to 50 hours of 
sleep deprivation in a crossover design. Lathosterol levels closely followed those of PCSK9 
in both groups. 
When morning samples from two experiments in which subjects had fasted for 2 or 7 days 
were evaluated we found that circulating PCSK9 levels were reduced by 70-80%. In parallel, 
serum lathosterol levels were reduced by 50-60 % . Serum cholesterol levels were 
unchanged, whereas serum ketone bodies increased. To exclude that ketosis per se may 
reduce PCSK9 levels we studied the effect of a ketogenic diet. Samples drawn in the morning 
after overnight fast before commencing the treatment, and at follow up, 1-16 months later, 
were analyzed. Although this fat and protein rich diet reduces glucose in a similar way as 
fasting, it did not reduce circulating PCSK9; instead lathosterol and total cholesterol levels 
increased by 24% and 37%, respectively. 
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LDLR numbers increase to similar extents during treatment with GH as with atorvastatin. 
However, when circulating PCSK9 was determined in samples from healthy subjects treated 
with increasing doses of GH and in samples from patients treated with atorvastatin, we found 
that GH treatment reduced circulating PCSK9 by 16% and atorvastatin treatment increased 
PCSK9 by 33%. 
Conclusion;  Throughout the day, and in response to fasting and cholesterol depletion, 
circulating PCSK9 displays marked variation, presumably related to oscillations in hepatic 
cholesterol that modify its activity in parallel with cholesterol synthesis. In addition to sterol 
mediated regulation, additional effects on LDL receptors may be mediated by hormones 
directly influencing PCSK9. 
4.3 PAPER III 
A vegan diet reduces serum LDL and oxidized LDL levels and raised atheroprotective natural 
antibodies against phosphorylcholine in patients with rheumatoid arthritis: a randomized 
study 
Aim: To characterize the effects of a vegan diet on blood lipids, oxidized LDL and on natural 
atheroprotective antibodies against phophorylcholine (anti PCs) in patients with rheumatoid 
arthritis. 
Results:  In a 12 month, randomized study, patients with rheumatoid arthritis (n=66), aged 
51±10, BMI 24±4kg/m2, were assigned to a vegan diet or a well-balanced non-vegan diet. 
Blood was collected at baseline, after 3 and 12 months. Thirty patients in the vegan group and 
28 in the non-vegan group completed at least 3 months of the diet regimen and were included 
in our analyses. Eight patients in the vegan group dropped out before completing 12 months 
of study.  
In the vegan diet group, total cholesterol and LDL-cholesterol were reduced after 3 and 12 
months compared to baseline, whereas TG and HDL-cholesterol did not change. OxLDL 
levels decreased after 3 months. When patients in the vegan diet group were separated in 
responders and non-responders at 12 months, the reduction in oxLDL levels was seen only in 
responders and was significant both at 3 and 12 months. In the non-vegan group, cholesterol 
and triglycerides were unaltered. In the vegan diet group IgA anti-PC levels was increased 
after 3 month compare to baseline. Levels of IgM anti-PC raised but did not reach statistical 
significance (p 0.057) following 12 month. In the non-vegan diet group, levels of IgM anti-
PC were reduced after 3 and 12 months regimen.  
Conclusion; a vegan diet given to patients with RA induces changes that are potentially 
atheroprotective and anti-inflammatory, including decreased LDL and oxLDL levels and 
increased anti-PC IgM and IgA levels 
 
  28 
4.4 PAPER IV 
Lowering of plasma cholesterol by a vegan diet is not related to changes in circulating PCSK9 
Aim: To test the hypothesis that reduced circulating PCSK9 levels explain the reduction of 
LDL cholesterol following a 12 month vegan diet intervention demonstrated in paper III.   
Of 66 patients with rheumatoid arthritis enrolled, 38 were randomized to a vegan diet and 28 
to a non–vegan diet for a period of one year. Twenty-two patients in the vegan diet group and 
25 in the non-vegan group completed the study, representing a dropout rate of 42% and 11 %, 
respectively, and were included in our analyses. All patients were sampled at baseline, and 
after 3 and 12 months on their respective diet. 
In the vegan diet group, total cholesterol was reduced after both 3 and 12 months by 13% and 
12%, respectively, as compared to baseline. VLDL cholesterol was reduced after 3 and 12 
months by 28% and 31%, respectively. LDL cholesterol was reduced after 3 months by 7%, 
dropping from 2. 0 (±0.81) to 1.9 (±0.70) mmol/L. HDL cholesterol increased after 12 month 
by 11%. No alterations in bile acid synthesis, cholesterol synthesis, or circulating PCSK9 
levels were observed during the regimen. In the non-vegan group there were no significant 
changes in the cholesterol variables during the study.  
Neither  circulating PCSK9 levels nor altered cholesterol or bile acid synthesis explain the 
beneficial effects on serum lipid profiles observed after a vegan diet for one year in patients 
with rheumatoid arthritis. 
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5 GENERAL DISCUSSION 
Cholesterol and bile acid homeostasis is under strict regulation from multiple mechanisms. 
The bile acid activated nuclear receptor FXR is central to maintain bile acid homeostasis via 
regulation of transporters in their enterohepatic circulation and of key enzymes in bile acid 
synthesis. In mice, numerous proteins have been proposed to be of regulatory importance 
following genetic gain- and loss-of-function experiments, such as FXR [85], SHP [86, 87], 
bile acid transporters including BSEP [116, 117] and ASBT, factors influencing conjugation 
[118, 119], klotho and FGF15.  Additional proteins discussed as of possible relevance to the 
regulation of bile acid synthesis are hepatic SHP2 [120] and intestinal Diet1 [121].The 
physiological importance of these pathways in humans remains to be determined.  
In paper I we studied the importance of circulating FGF19 as a regulator of bile acid 
synthesis during different cholestyramine treatment regimens. All observations in paper I are 
not fully compatible with the thinking that FGF19 is the major suppressor of bile acid 
synthesis in humans. During the normalization period, both after a single day of 
cholestyramine treatment and after long-time treatment, there were notable discrepancies 
between serum levels of FGF19 and the level of bile acid synthesis. Although the results from 
studying the onset of treatment would be well compatible with the concept that lowering of 
FGF19 results in a stimulation of bile acid synthesis, these observations indicate that an 
increased synthesis may remain also when FGF19 levels are normalized. This suggests that 
cholestyramine treatment may induce bile acid synthesis also via more direct hepatic 
pathways, independent of the circulating levels of FGF19. An alternative explanation for 
these discrepancies between the level of bile acid synthesis and FGF19 serum levels could be 
that the interaction between FGF19 and its receptor FGFR4 is modulated by cofactors which 
could modify the effect of circulating FGF19.  
In response to nutritional and hormonal signals, the liver regulates lipid and carbohydrate 
metabolic pathways to maintain homeostasis. In paper I, we further studied if changes in the 
presumed metabolic regulator FGF19 could explain the change in TG levels during 
cholestyramine treatment. We found that the elevated levels of TGs observed in healthy 
individuals developed unrelated to circulating levels of FGF19 or to the level of bile acid 
synthesis per se. During the night after a single day of treatment, TG strongly increased, 
peaked and declined to be doubled before breakfast. Further, glucose and insulin transiently 
increased during the night. In the morning after a single day of treatment FGF19 levels was 
strongly reduced  compared to baseline, while BA synthesis (reflected by C4c levels) and 
cholesterol synthesis (reflected by lathosterol/c levels) were increased. In the experiment 
where weekly step wise increases of cholestyramine doses were used, circulating FGF19 was 
accordingly reduced while the levels of TGs, glucose or insulin were unchanged. In the one 
day treatment experiment, total serum bile acids were strongly reduced concomitantly with 
elevated levels of TGs. In addition, bile acid composition was altered with an enlarged 
percent of DCA, displaying a pattern similar to one described among patients with type 2 
diabetes [122, 123]. Moreover, altered diurnal rhythms – non steady-state situations –  may 
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directly or indirectly influence levels of triglycerides and glucose. Furthermore, mechanisms 
regulating apoB assembly and secretion are not fully defined and PCSK9 may have a 
regulatory role on triglyceride rich lipoprotein production both in intestine [124] and liver 
[125]. 
By analyzing samples from studies of different experimental situations we have demonstrated 
that fasting strongly reduces circulating PCSK9 in healthy humans. This occurs 
concomitantly with a suppressed cholesterol synthesis, as monitored by lathosterol 
concentrations. Despite these pronounced dynamic changes, LDL cholesterol levels were not 
reduced. SREBP-2 activates genes required to generate PCSK9, HMG-CoA and LDLR. The 
strong correlation between PCSK9 and lathosterol observed in our studies makes it 
reasonable to believe that hepatic PCSK9 and HMG-CoA reductase are regulated by a 
common mechanism in these situations. In contrast, during long time cholestyramine 
treatment and in response to a ketogenic diet, PCSK9 and HMG-CoA may not correlate. To 
separate transcription of genes regulated in a coordinated manner may sometimes be 
advantageous. The efficiency of statins would be improved if regulation of PCSK9 and 
LDLR were separated [126]. During statin treatment a reduction in cholesterol synthesis 
(enzyme activity) together with an increase in the number of LDLRs and levels of circulating 
PCSK9 is demonstrated. What appears as a discrepancy between expression of PCSK9, 
HMG-CoA reductase and LDLR may not be a discrepancy at mRNA level, as statins inhibit  
the enzyme thereby stimulating its gene expression due to reduced hepatic cholesterol. The 
relationship between circulating PCSK9 and LDLR may be more complex due to the fact that  
20-40 % of plasma PCSK9 may be bound to apoB in LDL [127-129]. Thus, a reduction of 
hepatic LDLRs would result in a reduced clearance of PCSK9, leading to its accumulation in 
plasma. Accordingly, subjects with FH – particularly homozygotes - show significantly 
higher levels of circulating PCSK9 compared to healthy subjects [130]. Moreover, we could 
demonstrate that humans treated with GH had reduced serum PCSK9 levels (paper II), which 
could contribute to the LDL-lowering effect of GH in humans [107]. Circulating PCSK9 is 
also reduced by thyroid hormone, which may likely contribute to the lower plasma LDLC 
levels in hyperthyroidism [131]. Also increased levels of estrogen reduce both PCSK9 and 
LDL cholesterol in women [112], and variations in endogenous estrogen during the menstrual 
cycle may contribute to the intraindividual variation in PCSK9 and LDLC in normal women 
[57]. 
Diet composition and eating patterns influence cholesterol metabolism. Knowledge of 
underlying mechanisms provides the ability to modulate regulation and homeostasis in 
desired direction. A ketogenic diet (paper II) increased cholesterol synthesis by 24% and total 
plasma cholesterol by 37%, but did not influence levels of circulating PCSK9. A vegan diet 
(paper III) reduced total-C after 3 and 12 months. We further investigated the possible 
mechanism(s) implicated in this dietary effect, but could not find evidence for any 
involvement of PCSK9 or altered bile acid or cholesterol synthesis (paper IV). However, a 
randomized isocaloric trial for 10 weeks (HEPFAT) showed that PUFA, in contrast to SFA, 
decreased circulating PCSK9 in parallel with LDL cholesterol [132]. A Mediterranean diet 
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for 5 weeks in men with metabolic syndrome reduced LDL cholesterol and circulating 
PCSK9 [133]. Further studies on how diet may influence LDL metabolism through effects on 
PCSK9 in humans will be of great interest. Moreover, the gut microbiome responds to an 
altered diet [134]. The microbiome plays a part in in controlling the composition of the acid 
pool, and hence also modulates bile acid signaling [135-137]. 
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6 CONCLUSIONS 
From the studies following conclusions can be drawn 
 Circulating FGF19 is markedly influenced by the transintestinal flux of bile acids, 
whereas its proposed role in the suppression of BA synthesis and TG levels may not 
always apply.  
 Circulating PCSK9 has a diurnal variation and is strongly reduced during fasting in 
humans. These changes may relate to diurnal oscillations in hepatic intracellular 
cholesterol levels. 
 A vegan diet  reduced levels of oxLDL and LDL-cholesterol, and raised anti-PC IgA 
and IgM levels in patients with RA. 
 Changes in circulating PCSK9 or alterations in the synthesis of cholesterol or bile 
acids do not contribute to the improved lipid profile observed during a vegan diet. 
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